Is GlaxoSmithKline PLC Stock a Good Investment?
GlaxoSmithKline PLC Investment Advice | GSK |
- Examine GlaxoSmithKline PLC's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research GlaxoSmithKline PLC's leadership team and their track record. Good management can help GlaxoSmithKline PLC navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceutical Products space and any emerging trends that could impact GlaxoSmithKline PLC's business and its evolving consumer preferences.
- Compare GlaxoSmithKline PLC's performance and market position to its competitors. Analyze how GlaxoSmithKline PLC is positioned in terms of product offerings, innovation, and market share.
- Check if GlaxoSmithKline PLC pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about GlaxoSmithKline PLC's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in GlaxoSmithKline PLC ADR stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if GlaxoSmithKline PLC ADR is a good investment.
Sell | Buy |
Buy
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine GlaxoSmithKline PLC Stock
Researching GlaxoSmithKline PLC's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 17.0% of the company shares are owned by institutional investors. The book value of GlaxoSmithKline PLC was currently reported as 3.46. The company has Price/Earnings To Growth (PEG) ratio of 0.38. GlaxoSmithKline PLC ADR last dividend was issued on the 21st of February 2025. The entity had 1226:1000 split on the 22nd of July 2022.
To determine if GlaxoSmithKline PLC is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding GlaxoSmithKline PLC's research are outlined below:
| On 10th of April 2025 GlaxoSmithKline PLC paid $ 0.4007 per share dividend to its current shareholders |
GlaxoSmithKline PLC uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in GlaxoSmithKline PLC ADR. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to GlaxoSmithKline PLC's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 31st of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
GlaxoSmithKline PLC's market capitalization trends
The company currently falls under 'Large-Cap' category with a total capitalization of 79.45 B.GlaxoSmithKline PLC's profitablity analysis
The company has Net Profit Margin of 0.1 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.31 %, which entails that for every 100 dollars of revenue, it generated $0.31 of operating income.Determining GlaxoSmithKline PLC's profitability involves analyzing its financial statements and using various financial metrics to determine if GlaxoSmithKline PLC is a good buy. For example, gross profit margin measures GlaxoSmithKline PLC's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of GlaxoSmithKline PLC's profitability and make more informed investment decisions.
Basic technical analysis of GlaxoSmithKline Stock
As of the 4th of May, GlaxoSmithKline PLC retains the market risk adjusted performance of 1.21, and Risk Adjusted Performance of 0.1728. GlaxoSmithKline PLC technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.GlaxoSmithKline PLC's Outstanding Corporate Bonds
GlaxoSmithKline PLC issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GlaxoSmithKline PLC ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GlaxoSmithKline bonds can be classified according to their maturity, which is the date when GlaxoSmithKline PLC ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US377320AA45 Corp BondUS377320AA45 | View | |
| GLAXOSMITHKLINE CAPITAL PLC Corp BondUS377373AH85 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AM97 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AN70 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AB33 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AJ68 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AE71 | View |
Understand GlaxoSmithKline PLC's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing GlaxoSmithKline PLC's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1728 | |||
| Market Risk Adjusted Performance | 1.21 | |||
| Mean Deviation | 1.46 | |||
| Semi Deviation | 2.04 | |||
| Downside Deviation | 2.31 | |||
| Coefficient Of Variation | 967.26 | |||
| Standard Deviation | 2.08 | |||
| Variance | 4.32 | |||
| Information Ratio | 0.1545 | |||
| Jensen Alpha | 0.2247 | |||
| Total Risk Alpha | 0.3511 | |||
| Sortino Ratio | 0.1391 | |||
| Treynor Ratio | 1.2 | |||
| Maximum Drawdown | 14.57 | |||
| Value At Risk | (2.76) | |||
| Potential Upside | 3.1 | |||
| Downside Variance | 5.33 | |||
| Semi Variance | 4.16 | |||
| Expected Short fall | (1.47) | |||
| Skewness | 0.1365 | |||
| Kurtosis | 3.81 |
| Risk Adjusted Performance | 0.1728 | |||
| Market Risk Adjusted Performance | 1.21 | |||
| Mean Deviation | 1.46 | |||
| Semi Deviation | 2.04 | |||
| Downside Deviation | 2.31 | |||
| Coefficient Of Variation | 967.26 | |||
| Standard Deviation | 2.08 | |||
| Variance | 4.32 | |||
| Information Ratio | 0.1545 | |||
| Jensen Alpha | 0.2247 | |||
| Total Risk Alpha | 0.3511 | |||
| Sortino Ratio | 0.1391 | |||
| Treynor Ratio | 1.2 | |||
| Maximum Drawdown | 14.57 | |||
| Value At Risk | (2.76) | |||
| Potential Upside | 3.1 | |||
| Downside Variance | 5.33 | |||
| Semi Variance | 4.16 | |||
| Expected Short fall | (1.47) | |||
| Skewness | 0.1365 | |||
| Kurtosis | 3.81 |
Consider GlaxoSmithKline PLC's intraday indicators
GlaxoSmithKline PLC intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GlaxoSmithKline PLC stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
GlaxoSmithKline PLC time-series forecasting models is one of many GlaxoSmithKline PLC's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary GlaxoSmithKline PLC's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
GlaxoSmithKline Stock media impact
There is far too much social signal, news, headlines, and media speculation about GlaxoSmithKline PLC that are available to investors today. This information is accessible both publicly - through GlaxoSmithKline PLC's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of GlaxoSmithKline-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of GlaxoSmithKline PLC news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of GlaxoSmithKline PLC relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to GlaxoSmithKline PLC's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive GlaxoSmithKline PLC alpha.
GlaxoSmithKline PLC Corporate Directors
| Lynn Elsenhans | Independent Non-Executive Director | Profile | |
| Harry Dietz | Non-Executive Independent Director, Scientific and Medical Expert | Profile | |
| Charles Bancroft | Non-Executive Independent Director | Profile | |
| Vivienne Cox | Independent Non-Executive Director and Workforce Engagement Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between GlaxoSmithKline PLC's value and its price, as these two are different measures arrived at by various means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.